Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease
Abstract Introduction People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods Noradrenaline, adrenaline, and their metabolite 3‐methoxy‐4‐hydr...
Main Authors: | Alain D. Dekker, Yannick Vermeiren, Maria Carmona‐Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean‐Jacques Martin, Netherlands Brain Bank, Rafael Blesa, Juan Fortea, Peter P. De Deyn |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1016/j.dadm.2017.11.001 |
Similar Items
-
Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
by: Jana Janssens, et al.
Published: (2018-01-01) -
Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs
by: Dubravka Svob Strac, et al.
Published: (2016-11-01) -
Monoaminergic and histaminergic strategies and treatments in brain diseases
by: Giuseppe Di Giovanni, et al.
Published: (2016-11-01) -
Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
by: Bessy Benejam, et al.
Published: (2020-01-01) -
Monoaminergic Modulation of Motor Cortex Function
by: Clément Vitrac, et al.
Published: (2017-10-01)